Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
Healthcare
$8.04 +1.97%
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
52W Low $5.85High $24.17
Volume 0.64M
Average 0.43M
Income Statement
Follow revenue through to earnings.
Revenue
$67.22M
FY 2025 · Annual
-51.4% YoYOperating Income
-$74.95M
FY 2025 · Annual
Net Income
-$65.78M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.36M | 205.76M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.03M |
| Gross Profit | 12.36M | 205.76M | 157.75M | 138.39M | 64.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| Research & Development | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| Selling, General & Admin | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| Operating Expenses | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| EBITDA | (199.81M) | 15.17M | (24.17M) | (77.4M) | (62.76M) |
| EBITDA Margin | -1616.7% | 7.4% | -15.3% | -55.9% | -93.4% |
| Operating Income | (202.85M) | 12.18M | (78.21M) | (95.67M) | (74.96M) |
| Operating Margin | -1641.3% | 5.9% | -49.6% | -69.1% | -111.5% |
| Interest Income | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 2.67M | 3M | 767K | 0 | 0 |
| Other Income / Expenses | (822K) | (1.53M) | 50.32M | 14.72M | 9.17M |
| Income Before Tax | (203.67M) | 10.64M | (27.89M) | (80.95M) | (65.78M) |
| Pre-Tax Margin | -1648.0% | 5.2% | -17.7% | -58.5% | -97.9% |
| Income Tax Expense | 0 | 1.3M | 1.84M | (4K) | 0 |
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Net Margin | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (Basic) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| EPS (Diluted) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| 26.32M | 26.45M | 26.63M | 27M | 27.39M | |
| 26.32M | 27.09M | 26.63M | 27M | 27.39M |
ARCT Earnings Waterfall · TTM
NASDAQ:ARCT · Revenue to Net Income
Key Ratios
EPS$-2.83
Gross Margin68.2%
Net Margin-1370.0%
P/E Ratio-5.6
P/S Ratio114.4
Analysis
$45.4M of revenue converted into -$78.7M of net income for the selected period. Gross margin is 68.2% and net margin is -1370.0%, showing how much revenue survives after costs and taxes. EPS is $-2.83, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 |
How much revenue does ARCT generate?
Arcturus Therapeutics Holdings Inc. (ARCT) reported $67.22M of revenue in fiscal 2025.
Is ARCT profitable?
Arcturus Therapeutics Holdings Inc. (ARCT) reported -$65.78M of net income, with a net margin of -97.9%.
Continue the stock analysis
Jump to another research area for this company.